Total Payments
$181,977
2024 Payments
$2,037
Companies
25
Transactions
540
Medicare Patients
4,384
Medicare Billing
$727,706
Payment Breakdown by Category
Other$152,403 (83.7%)
Travel$14,185 (7.8%)
Consulting$7,992 (4.4%)
Food & Beverage$7,342 (4.0%)
Education$55.89 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $152,403 | 90 | 83.7% |
| Travel and Lodging | $14,185 | 62 | 7.8% |
| Consulting Fee | $7,992 | 10 | 4.4% |
| Food and Beverage | $7,342 | 361 | 4.0% |
| Education | $55.89 | 17 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $70,455 | 106 | $0 (2023) |
| Mylan Specialty L.P. | $48,394 | 126 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $28,958 | 91 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $19,756 | 65 | $0 (2021) |
| Actelion Pharmaceuticals US, Inc. | $11,115 | 44 | $0 (2022) |
| ViiV Healthcare Company | $1,600 | 1 | $0 (2019) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $396.87 | 21 | $0 (2023) |
| United Therapeutics Corporation | $225.50 | 30 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $177.21 | 9 | $0 (2024) |
| Genentech USA, Inc. | $135.92 | 8 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,037 | 18 | AstraZeneca Pharmaceuticals LP ($1,788) |
| 2023 | $15,034 | 29 | GlaxoSmithKline, LLC. ($11,554) |
| 2022 | $17,488 | 47 | GlaxoSmithKline, LLC. ($13,258) |
| 2021 | $38,853 | 87 | GlaxoSmithKline, LLC. ($19,413) |
| 2020 | $38,561 | 95 | GlaxoSmithKline, LLC. ($22,227) |
| 2019 | $34,382 | 123 | Mylan Specialty L.P. ($21,213) |
| 2018 | $20,361 | 78 | Sunovion Pharmaceuticals Inc. ($12,718) |
| 2017 | $15,261 | 63 | Actelion Pharmaceuticals US, Inc. ($9,347) |
All Payment Transactions
540 individual payment records from CMS Open Payments — Page 1 of 22
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/14/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $32.10 | General |
| 10/17/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $950.00 | General |
| Category: Respiratory | ||||||
| 10/10/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $24.88 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/09/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Food and Beverage | In-kind items and services | $35.71 | General |
| Category: NEUROLOGY | ||||||
| 10/01/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $26.08 | General |
| Category: Respiratory | ||||||
| 08/29/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $300.00 | General |
| Category: Respiratory | ||||||
| 08/22/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $28.55 | General |
| 08/15/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $300.00 | General |
| Category: Respiratory | ||||||
| 07/30/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $20.91 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 07/04/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $150.00 | General |
| Category: Respiratory | ||||||
| 06/18/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $17.58 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 05/08/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $21.17 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 04/24/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $19.34 | General |
| Category: Obesity | ||||||
| 03/07/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Food and Beverage | In-kind items and services | $23.66 | General |
| Category: NEUROLOGY | ||||||
| 03/05/2024 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $21.77 | General |
| Category: Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | ||||||
| 02/26/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $20.40 | General |
| Category: ANTIBIOTIC | ||||||
| 02/19/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $27.33 | General |
| 01/29/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $17.66 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/13/2023 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $300.00 | General |
| Category: Respiratory | ||||||
| 11/08/2023 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Food and Beverage | In-kind items and services | $23.10 | General |
| Category: NEUROLOGY | ||||||
| 11/01/2023 | GlaxoSmithKline, LLC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| 11/01/2023 | United Therapeutics Corporation | TYVASO (Drug) | Food and Beverage | In-kind items and services | $18.16 | General |
| Category: PAH | ||||||
| 10/19/2023 | GlaxoSmithKline, LLC. | — | Travel and Lodging | In-kind items and services | $1,080.00 | General |
| 10/12/2023 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $18.29 | General |
| Category: ANTIBIOTIC | ||||||
| 10/11/2023 | GlaxoSmithKline, LLC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 1,093 | 2,266 | $618,147 | $181,645 |
| 2022 | 13 | 1,203 | 2,348 | $628,563 | $184,542 |
| 2021 | 14 | 1,070 | 2,287 | $669,270 | $199,809 |
| 2020 | 12 | 1,018 | 1,983 | $575,565 | $161,709 |
Total Patients
4,384
Total Services
8,884
Medicare Billing
$727,706
Procedure Codes
52
All Medicare Procedures & Services
52 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 128 | 325 | $162,500 | $52,673 | 32.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 130 | 313 | $88,266 | $40,057 | 45.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 55 | 224 | $39,206 | $20,261 | 51.7% |
| 95810 | Sleep study in sleep lab (6 years or older) | Office | 2023 | 24 | 25 | $73,750 | $11,267 | 15.3% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 142 | 331 | $33,100 | $9,269 | 28.0% |
| 95811 | Sleep study in sleep lab with continuous airway pressure (6 years or older) | Office | 2023 | 18 | 18 | $64,800 | $8,485 | 13.1% |
| 95070 | Test for allergy using drugs | Office | 2023 | 141 | 332 | $25,000 | $8,285 | 33.1% |
| 94618 | Test for exercise-induced lung stress | Office | 2023 | 141 | 330 | $72,600 | $8,086 | 11.1% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 116 | 142 | $14,200 | $5,918 | 41.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 35 | 35 | $12,150 | $5,804 | 47.8% |
| 94726 | Test to determine lung volumes using sensors | Office | 2023 | 114 | 140 | $14,000 | $5,607 | 40.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 35 | 35 | $11,375 | $4,615 | 40.6% |
| 32555 | Aspiration of fluid from chest cavity using imaging guidance | Facility | 2023 | 14 | 16 | $7,200 | $1,320 | 18.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 152 | 318 | $88,163 | $42,913 | 48.7% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 48 | 247 | $123,500 | $41,581 | 33.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 53 | 234 | $40,950 | $18,354 | 44.8% |
| 95811 | Sleep study in sleep lab with continuous airway pressure (6 years or older) | Office | 2022 | 27 | 27 | $91,200 | $12,546 | 13.8% |
| 95810 | Sleep study in sleep lab (6 years or older) | Office | 2022 | 24 | 26 | $74,200 | $11,573 | 15.6% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2022 | 177 | 356 | $35,600 | $10,240 | 28.8% |
| 95070 | Test for allergy using drugs | Office | 2022 | 177 | 356 | $26,700 | $9,290 | 34.8% |
| 94618 | Test for exercise-induced lung stress | Office | 2022 | 172 | 345 | $75,900 | $8,633 | 11.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 51 | 51 | $17,850 | $8,571 | 48.0% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2022 | 149 | 186 | $18,600 | $7,990 | 43.0% |
| 94726 | Test to determine lung volumes using sensors | Office | 2022 | 125 | 145 | $14,500 | $5,884 | 40.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 33 | 34 | $11,050 | $5,006 | 45.3% |
About Dr. Mir-Omar Ali, MD
Dr. Mir-Omar Ali, MD is a Critical Care Medicine healthcare provider based in Clayton, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/24/2007. The National Provider Identifier (NPI) number assigned to this provider is 1083800965.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mir-Omar Ali, MD has received a total of $181,977 in payments from pharmaceutical and medical device companies, with $2,037 received in 2024. These payments were reported across 540 transactions from 25 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($152,403).
As a Medicare-enrolled provider, Ali has provided services to 4,384 Medicare beneficiaries, totaling 8,884 services with total Medicare billing of $727,706. Data is available for 4 years (2020–2023), covering 52 distinct procedure/service records.
Ad
Practice Information
- Specialty Critical Care Medicine
- Other Specialties Pulmonary Disease
- Location Clayton, NC
- Active Since 09/24/2007
- Last Updated 11/11/2019
- Taxonomy Code 207RC0200X
- Entity Type Individual
- NPI Number 1083800965
Products in Payments
- TRELEGY ELLIPTA (Drug) $58,649
- Yupelri (Drug) $43,300
- LONHALA MAGNAIR (Drug) $19,563
- BREZTRI (Drug) $16,895
- BEVESPI AEROSPHERE (Drug) $7,668
- OPSUMIT MACITENTAN (Drug) $6,244
- YUPELRI (Drug) $4,978
- SYMBICORT (Drug) $3,857
- OPSUMIT (Drug) $247.42
- FASENRA (Drug) $188.09
- OFEV (Drug) $171.92
- ANORO ELLIPTA (Drug) $154.13
- TYVASO (Drug) $153.80
- Xolair (Biological) $135.92
- STIOLTO RESPIMAT (Drug) $121.22
- XYWAV (Drug) $117.80
- FARXIGA (Drug) $102.02
- Dymista (Drug) $94.33
- Prolastin-C Liquid (Biological) $82.28
- BREZTRI AEROSPHERE (Drug) $81.90
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.